Mechanisms regulating response to anti-PD-1 therapy in lung cancer are not well defined. This study, using orthotopic immunocompetent mouse models of lung cancer, demonstrates that intrinsic sensitivity of cancer cells to IFN determines anti-PD-1 responsiveness through alterations in the tumor microenvironment.
Introduction:
The development of immune checkpoint inhibitors has shown great promise in a wide variety of malignancies including lung cancer. However, only ~20% of unselected non-small cell lung cancer (NSCLC) patients respond to monotherapy targeting the PD-1/PD-L1 axis [1] [2] [3] .
Previous studies have correlated multiple factors with patient response to immunotherapy.
These include tumor mutational burden, the presence of neoantigens, PD-L1 expression on the surface of tumor cells and/or surrounding stromal cells, tumor-infiltrating immune cells, as well as patient smoking status [4] [5] [6] [7] [8] [9] [10] [11] . Importantly, Ayers et. al defined an interferon-gamma (IFN) gene signature generated from melanoma patient tumors that correlated with enhanced response to pembrolizumab across multiple cancer types [9] . While many clinical trials involving single-agent immunotherapy or combination therapies are being performed in NSCLC, a mechanistic understanding of determinants of response to these agents is still incomplete.
These studies require preclinical models that recapitulate features of human lung cancer.
Our laboratory has employed an orthotopic immunocompetent mouse model to study how K-Ras mutant lung cancers respond to the immune system [12] [13] [14] [15] . In this model lung cancer cells derived from C57BL/6J mice are implanted directly into the lungs of syngeneic mice. These cells form a primary tumor after 2-4 weeks that metastasizes to the other lung lobes, liver, brain, and mediastinum [16] . This model has the advantage that tumors develop in the appropriate tumor microenvironment (TME). In addition, the non-synonymous mutational burden in these tumors is comparable to human lung tumors, and significantly higher than genetically engineered mouse models [17] , allowing for recognition by the adaptive immune system. We have previously demonstrated differential sensitivity of K-Ras mutant tumors to anti-PD-1/anti-PD-L1 therapy, with CMT167 tumors showing a strong inhibition and Lewis Lung Carcinoma (LLC) tumors being generally unresponsive [13] . The responsiveness of these tumors was also dependent on specific features of the lung TME. CMT167 tumors implanted subcutaneously were resistant to anti-PD-1 therapy whereas tumors in the lung were eliminated. Thus, this model allows us to define specific features of cancer cells that determine the Page 4 of 32 response to immunotherapy. In this study we have focused on how cancer cell-intrinsic response to IFN affects the TME and response to anti-PD-1 therapy.
IFN is made predominantly by Natural Killer (NK), type 1 Innate Lymphoid (ILC1) and T cells [18, 19] . Since the 1990s it has been shown that IFN increases the immunogenicity of some tumors [20] . IFN binds to cell surface receptors (IFNGR1/ IFNGR2) on cancer cells resulting in activation of JAK1 and JAK2 and phosphorylation of STAT1 [20] . Activated STAT1 dimers translocate to the nucleus to initiate waves of transcription that can lead to enhanced MHC Class I and II presentation on tumor cells, and increased chemokine expression. Global loss of IFN is detrimental to tumor surveillance in mice, as Ifn -/-mice develop tumors more quickly than their Ifn +/+ counterparts in the setting of carcinogen-induced or spontaneously arising tumors [21, 22] . Tumors that are insensitive to IFN can grow equally well in Ifn -/-or Ifn +/+ mice, suggesting that host response does not completely alter the growth of these tumors [23] . Thus, it has been speculated that many tumors develop mutations in the IFN signaling pathway in order to evade the immune system. Recent studies have shown that approximately ~30% of both melanoma and lung carcinomas have at least one mutation in the IFN pathway including JAK1, IFNGR1, or IFNGR2 [20] , and resistance to checkpoint inhibitors in patients is associated with JAK1/2 mutations [24] .
We hypothesized that intrinsic differences in the responsiveness of cancer cells to IFN, distinct from other features of these cells, define the nature of the TME and control sensitivity of lung tumors to immunotherapy. In this study we demonstrated this by molecularly-altering responsiveness of murine lung cancer cells and defining changes in the TME that regulate responsiveness to anti-PD-1 therapy.
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Materials and Methods:
Cells : Murine Lewis Lung Carcinoma (LLC) cells expressing firefly luciferase were purchased from Caliper Life Sciences and maintained in DMEM (#10-017-CV, Corning) supplemented with 10% FBS, penicillin/streptomycin, and G418 (500ng/mL). LLC cells harbor a heterozygous KRas G12V mutation [13] . CMT167 cells (gift of Dr. Alvin Malkinson, University of Colorado) were transduced with firefly luciferase and maintained in DMEM (#10-017-CV, Corning) with 10%
FBS, penicillin/streptomycin, and G418 (500ng/mL) [16] . CMT167 cells harbor a K-Ras G12C mutation [13] . Cell lines were confirmed mycoplasma-negative every two weeks and were last tested January 2019 (Lonza, # LT07-703). To maintain cellular phenotypes and to prevent cross-contamination of murine cell lines, cells were grown in vitro for less than 10 passages, and for only 2-3 weeks before use in in vivo experiments. Cell phenotypes were regularly assessed via proliferation assays, and EMT status. No phenotypic changes were observed during the course of these studies. [16] . For subcutaneous tumor cell implantation, animals
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were implanted with 1x10 6 cells in the flank. was also added to viral supernatant generated from HEK293T cells and was filtered through a 0.45µm filter before media was placed on LLC or CMT167 cells. Stable cells were then selected by resistance to puromycin treatment (2 g/mL). Pools of transduced cells were screened for degree of knockdown by mRNA and protein relative to parental cell lines and to the non-targeting control cells. For CMT167 transduced cells, knockdowns were subcloned and are subsequently represented as "CMT-sh68sc3" or "CMT-sh69sc2". For in vitro experiments, cells were treated with recombinant murine IFN (0-100 ng/mL) (PeproTech #315-05) followed by isolation of protein and/or RNA for immunoblotting and quantitative real-time-PCR (qRT-PCR).
Immunoblotting: Cells were washed 3X with PBS, followed by lysis with MAPK Buffer(50 mM -glycerophosphate, pH 7.2, 0.5% Triton X-100, 5 mM EGTA, 100 μM sodium orthovanadate, 1 mM dithiothreitol, and 2 mM MgCl2) and a protease inhibitor cocktail from Sigma (Sigma #P8340). 10-40 μg of total protein was fractionated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes. Antibodies used were: pSTAT1 (Y701)
Cell Signaling #9167S (1:500-1:1000); STAT1, Cell Signaling #9172S (1:1,000-1:1,500); FIJI.
Flow Cytometry: Mice were sacrificed between 2-4 weeks post-tumor cell injection. Tumorbearing left lung lobes were excised, mechanically dissociated, and incubated at 37°C for 30 minutes with collagenase type II (8480 U/ml, Worthington Biochemical), elastase (7.5mg/ml, Worthington Biochemical), and soybean trypsin inhibitor (2mg/ml, Worthington Biochemical).
After which, single-cell suspensions were made and filtered through 70 µm cell strainers (BD), subjected to red blood cells lysis using hypotonic buffer (0.15 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2), and filtered again through 40 µm cell strainers (BD) [12] . All viable singlet (19Ir +, 193Ir +, 195Pt +) events were imported into cytofkit analysis pipeline and 39 markers were selected for clustering. The merge method 'min' was selected (12, 255 events from each file used for clustering) and the files were transformed via the cytofAsinh method. Then files were clustered with the PhenoGraph algorithm and tsne was selected as the visualization method. PhenoGraph identified 35 unique clusters. These results were visualized via the R package "Shiny" where labels, dot size, and cluster color were customized according to cluster identity or phenotype. Plots were examined for expression of various cellular markers (parameters). The algorithm produced multiple .csv files, the files "cluster median data" and "cluster cell percentage" which were utilized to determine cluster frequency and phenotype. via the TopHat v2 software [15] . The aligned read files were then processed by Cufflinks v2.0.2 software in order to determine the relative abundance of mRNA transcripts [15] . Reads are portrayed as Fragments Per Kilobase of exon per million fragments mapped (FPKM). For 
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LLC Cells Exhibit a Blunted Response to IFN In Vitro and In Vivo Compared to CMT167
We hypothesized that the differential response of CMT167 versus LLC orthotopic tumors to anti-PD-1 therapy was mediated at least in part through inherent differences in the cancer cells and how they respond to signals coming from the tumor microenvironment (TME) Additionally, CMT167 cells showed a more robust and sustained induction of phospho-STAT1
(p-STAT1), and total STAT1 levels upon treatment with IFN compared to LLC cells ( Figure   1F ). Collectively these data suggest that responsiveness of the cancer cells to IFN signaling is associated with sensitivity to anti-PD-1 therapy in our model. These data indicate that the IFN responsiveness of CMT167 cells is critical for their response to immunotherapy.
Silencing Ifngr1 in CMT167 Confers
Silencing Socs1 in the LLC Line Confers Increased Response to IFN In Vitro
Since the lack of an IFN response in LLC cells is not due to lack of receptor expression, we examined differences in expression of putative regulators of the IFN pathway between the responsive CMT167 and unresponsive LLC cell lines. We determined that at baseline, LLC cells expressed markedly higher levels of Socs1, or suppressor of cytokine signaling 1, which is a critical negative regulator of interferon signaling ( Figure 3A ) [27, 28] . We confirmed that LLC cells expressed higher levels of both SOCS1 protein and mRNA relative to CMT167 cells in vitro (Figure 3B-C) . These data led us to hypothesize that high baseline levels of 
Socs1 KD Tumors Show Enhanced Response to Anti-PD-1 Therapy
To determine if altering the sensitivity of LLC cells to IFN affects tumor growth in vivo and responsiveness to anti-PD-1, we implanted LLC-NT or LLC-sh21 cells into the lungs of syngeneic WT mice. Tumors were allowed to establish for 1 week and were then treated with either an anti-PD-1 antibody or an isotype control antibody (IgG2a) for 2 weeks (as above).
Similar to the parental LLC line as previously published [13] , there was no significant difference in primary tumor volume between the LLC-NT tumors treated with anti-PD-1 or isotype control after 3 weeks (Figure 3F) . However, in mice harboring LLC-sh21 tumors, treatment with the anti-PD-1 antibody decreased primary tumor volume by over 80%, a statistically significant difference compared to all the other experimental groups ( Figure 3F ). To determine if these effects were specific to the lung TME, we analyzed the response of LLC-sh21 cells implanted subcutaneously to anti-PD-1 therapy. Unlike what was observed in orthotopic lung tumors, subcutaneous LLC-sh21 tumors were resistant to anti-PD-1 therapy ( Figure 3G ). This is similar to our previous data showing that the sensitivity of CMT167 tumors to anti-PD-1 therapy was specific to tumors implanted into the lung, while identical cells implanted subcutaneously were resistant [13] . These data suggest enhanced responsiveness of LLC tumors to anti-PD-1 is dependent on critical features of the lung TME that are absent in subcutaneous models.
Socs1 KD Tumors Show Alterations in Multiple Populations
To define changes in the TME that are dependent on the IFN-responsiveness of the LLC cells, we used mass cytometry (CyTOF) to characterize both CD45 + and CD45 -populations from LLC-NT and LLC-sh21 tumors prior to treatment with anti-PD-1 using a panel of 39 different antibodies. Three independent isolations using 3 mice/isolation were analyzed. There were no significant differences in tumor size between LLC-NT and LLC-sh21 at this time point (Supplemental Figure 3A) . Using the Phenograph algorithm, which allows unbiased clustering of events based on cellular distribution and phenotype, we identified 35 distinct clusters in the naïve, LLC-NT and LLC-sh21 experimental conditions [29] . Figure 4A depicts the tSNE plot for all samples, with clusters colored by phenotype. Phenotypes were defined based on the expression level of cellular markers (parameters) (Supplemental Figure 3B) . No significant differences were noted between the replicates (Supplemental Figure 3C) . is not reflected in vivo (Supplemental Figure 3E) .
In addition to populations of tumor cells, we examined differences in inflammatory and
immune cells between LLC-NT and LLC-sh21 tumors by examining CD45 + cell populations. We have previously profiled macrophage populations in LLC tumors using conventional flow cytometry [15] . We found that a population of recruited macrophages, defined as (Figure 4A-B) .
Since we observed low levels of PD-L1 on both LLC-NT and LLC-sh21 tumor cells in vivo, we wanted to determine if expression of PD-L1 on non-tumor cells was altered in mice implanted with LLC-sh21 Socs1 knockdown cancer cells [13] . While the overall frequency of CD64 + myeloid cells was comparable between LLC-NT and LLC-sh21 tumors, the relative distribution of macrophages expressing variable PD-L1 levels was altered (Figure 5A-B) .
Recruited monocytes (Cluster #2 Figure 5F ). These results indicate that the PD-L1 from the tumor microenvironment is critical for host response to anti-PD-1 treatment.
Socs1 KD Tumors Exhibit a More T-cell Inflamed Phenotype and Alterations in Macrophage Composition
While not statistically significant, we observed an increase in CD4 + and CD8 + T cell Changes in T cells were also analyzed by flow cytometry (Supplemental Figure 4D) .
By flow, we observed a significant increase in CD8 + T cells expressing PD-1 ( Figure 6E) 
Socs1 KD Tumors Have Elevated Levels of Cxcl9:
Since we observed increased tumor-infiltrating T cells in LLC-sh21 Socs1 KD tumors, as well as increased CD8 + T cell activation, we sought to identify cancer cell-intrinsic factors that could mediate these effects. We therefore recovered LLC-NT and LLC-sh21 cancer cells implanted into GFP-expressing transgenic mice and compared gene expression profiles with the respective cells grown in vitro using RNA-Seq (as in Figure 1 ). These data showed that Socs1 expression was decreased by approximately 60% in LLC-sh21 compared LLC-NT tumors,
confirming that these cells in vivo were still silenced for Socs1 (data not shown). We identified 45 genes that were differentially expressed between the LLC-NT and LLC-sh21 cells in vivo (Supplemental Table 1 ) has been associated with responsiveness to anti-PD-1 therapy in lung cancer and others malignancies [9] . However, whether this is associated with cancer cells alone or the surrounding TME has not been well examined. We hypothesized that sensitivity of cancer cells to IFN is a major regulator of the TME, and that altering the sensitivity of the cancer cells would as a gene associated with immunosuppression and tumor progression. In melanoma, increased copy number of Socs1 was found in tumors resistant to anti-CTLA therapy [30] . In human lung tumors, MET activation was associated with increased Socs1 expression and escape from immunotherapy [32] . Conversely, chemotherapeutic agents were shown to down regulate Socs1 through induction of miR-155, resulting in increased activation of CD8 + T cells [33] .
We anticipated that LLC-sh21 cells would express higher levels of CXCL9 in vivo, which we detected by message in tumor sections. Due to elevated Cxcl9 expression in these tumors, there were more recruited and activated T cells--particularly CD8 + T cells. These results are indicative of a more "T cell inflamed tumor" which is associated with better response to checkpoint inhibitors [5] . Though we anticipated increased expression of PD-L1 on LLC-sh21 cancer cells in vivo, which would promote a T cell-rich microenvironment with high PD-L1 expression, and subsequent sensitivity to anti-PD-1, LLC-sh21 cells recovered from tumors only showed a modest induction of PD-L1 compared to LLC-NT cells (data not shown). This could be explained by only a subset of the cancer cells expressing PD-L1, for example at the tumor edge. In our previous studies, PD-L1 expression on CMT167 cells, which are sensitive to IFN and checkpoint inhibition, was not detected on all cancer cells [13] . represent the mean of the data ±SEM after a two-way ANOVA (4C-E) (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
